Influence of patient‐reported outcomes on the treatment effect of deferasirox film‐coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis

Deferasirox dispersible tablets (DT), a once-daily, oral iron chelator, were approved by the US Food and Drug Administration in 2005. Deferasirox DT is typically dispersed in water or juice (20-30 mg/kg/day) and taken on an empty stomach ≥30 minutes before a meal.1 For patients to receive the maximum therapeutic benefit from chelation therapy, adherence to the prescribed dosing regimen is essential. Treatment satisfaction can affect adherence...